Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Corvus Pharmaceuticals Inc (CRVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: CRVS (5-star) is a WEAK-BUY. BUY since 15 days. Profits (-0.51%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
6 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $15.2
Year Target Price $15.2
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 877.22% | Avg. Invested days 35 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 299.98M USD | Price to earnings Ratio - | 1Y Target Price 15.2 |
Price to earnings Ratio - | 1Y Target Price 15.2 | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 1.75 - 10.00 | Updated Date 06/29/2025 |
52 Weeks Range 1.75 - 10.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
Earnings Date
Report Date 2025-06-13 | When After Market | Estimate -0.12 | Actual -0.1378 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -39.21% | Return on Equity (TTM) -100.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 256531360 | Price to Sales(TTM) - |
Enterprise Value 256531360 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.36 | Shares Outstanding 77114600 | Shares Floating 63154573 |
Shares Outstanding 77114600 | Shares Floating 63154573 | ||
Percent Insiders 3.83 | Percent Institutions 49.05 |
Analyst Ratings
Rating 4.83 | Target Price 15.2 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Corvus Pharmaceuticals Inc
Company Overview
History and Background
Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology therapies. Founded in 2011, it has progressed through multiple clinical trials with its lead product candidates, aiming to improve outcomes for cancer patients.
Core Business Areas
- Immunooncology Therapies: Development of small molecule and antibody therapies designed to target the immune system to fight cancer.
Leadership and Structure
The company is led by a management team with experience in drug development and oncology. Its organizational structure includes departments for research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- Soquelitin (CPI-444): A selective adenosine A2A receptor antagonist being developed for various cancers, often in combination with other therapies. No current market share as it is still in clinical trials. Competitors are other companies developing A2A receptor antagonists or combination therapies for similar cancers.
- CPI-818: A novel ITK inhibitor in Phase 1 clinical development for T cell lymphomas. No current market share as it is still in clinical trials. Competitors are companies developing ITK inhibitors or therapies for T cell lymphomas.
Market Dynamics
Industry Overview
The immuno-oncology industry is rapidly evolving, with increasing focus on combination therapies and novel targets to improve patient outcomes. It's a highly competitive landscape with many players of different sizes.
Positioning
Corvus is positioned as an innovator in immuno-oncology, focused on developing novel small molecule and antibody therapies. Its competitive advantage lies in its unique targets and combination therapy approach.
Total Addressable Market (TAM)
The TAM for immuno-oncology is estimated to reach hundreds of billions of dollars globally. Corvus is positioned to capture a share of this market with successful development and commercialization of its product candidates.
Upturn SWOT Analysis
Strengths
- Novel immuno-oncology targets
- Experienced management team
- Strong intellectual property portfolio
- Promising early clinical data
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently marketed products
- High risk of clinical trial failure
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or licensing
- Positive clinical trial results leading to regulatory approval
- Advancements in immuno-oncology research
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
Corvus faces intense competition from established pharmaceutical companies with larger resources and marketed products. Its competitive advantage lies in its novel targets and combination therapy approach, but it needs to demonstrate clinical efficacy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been primarily driven by clinical development progress.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization. Analyst estimates vary widely depending on the success of Soquelitin and CPI-818.
Recent Initiatives: Recent initiatives include advancing clinical trials for Soquelitin and CPI-818, and exploring potential partnerships.
Summary
Corvus Pharmaceuticals is a clinical-stage company with promising immuno-oncology assets, but faces high risks associated with drug development. Positive clinical trial results are critical for its future success. The company's focus on novel targets and combination therapies could provide a competitive advantage in the crowded immuno-oncology landscape. However, it must secure additional funding or partnerships to continue clinical development and commercialization. Ultimately, the company's success hinges on proving the efficacy and safety of its product candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Corvus Pharmaceuticals Inc. investor relations
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It is not financial advice and should not be used as the sole basis for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Corvus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2016-03-23 | Co-Founder, President, CEO & Chairman of the Board Dr. Richard A. Miller M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 31 | Website https://www.corvuspharma.com |
Full time employees 31 | Website https://www.corvuspharma.com | ||
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.